Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

95 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Anterior cervical discectomy with or without fusion with ray titanium cage: a prospective randomized clinical study.
Hauerberg J, Kosteljanetz M, Bøge-Rasmussen T, Dons K, Gideon P, Springborg JB, Wagner A. Hauerberg J, et al. Among authors: kosteljanetz m. Spine (Phila Pa 1976). 2008 Mar 1;33(5):458-64. doi: 10.1097/BRS.0b013e3181657dac. Spine (Phila Pa 1976). 2008. PMID: 18317187 Clinical Trial.
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, Kosteljanetz M, Lassen U. Poulsen HS, et al. Among authors: kosteljanetz m. Acta Oncol. 2009;48(1):52-8. doi: 10.1080/02841860802537924. Acta Oncol. 2009. PMID: 19031176 Clinical Trial.
Patients received bevacizumab (10 mg/kg) and irinotecan [340 mg/m(2) for those receiving enzyme-inducing antiepileptic drugs (EIAEDs) and 125 mg/m(2) for those not receiving EIAEDs] every 2 weeks. ...
Patients received bevacizumab (10 mg/kg) and irinotecan [340 mg/m(2) for those receiving enzyme-inducing antiepileptic drugs (EIAEDs) …
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS. Hasselbalch B, et al. Among authors: kosteljanetz m. Neuro Oncol. 2010 May;12(5):508-16. doi: 10.1093/neuonc/nop063. Epub 2010 Feb 5. Neuro Oncol. 2010. PMID: 20406901 Free PMC article. Clinical Trial.
Irinotecan dose was based on whether patients were taking enzyme-inducing antiepileptic drugs or not: 340 and 125 mg/m(2), respectively. Cetuximab 400 mg/m(2) as loading dose followed by 250 mg/m(2) weekly was administered IV. Forty-three patients were enroll …
Irinotecan dose was based on whether patients were taking enzyme-inducing antiepileptic drugs or not: 340 and 125 mg/m(2), respective …
Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.
Urup T, Michaelsen SR, Olsen LR, Toft A, Christensen IJ, Grunnet K, Winther O, Broholm H, Kosteljanetz M, Issazadeh-Navikas S, Poulsen HS, Lassen U. Urup T, et al. Among authors: kosteljanetz m. Mol Oncol. 2016 Oct;10(8):1160-8. doi: 10.1016/j.molonc.2016.05.005. Epub 2016 May 26. Mol Oncol. 2016. PMID: 27262894 Free PMC article.
Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.
Urup T, Dahlrot RH, Grunnet K, Christensen IJ, Michaelsen SR, Toft A, Larsen VA, Broholm H, Kosteljanetz M, Hansen S, Poulsen HS, Lassen U. Urup T, et al. Among authors: kosteljanetz m. Acta Oncol. 2016;55(4):418-22. doi: 10.3109/0284186X.2015.1114679. Epub 2016 Feb 1. Acta Oncol. 2016. PMID: 26828563
Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.
Michaelsen SR, Christensen IJ, Grunnet K, Stockhausen MT, Broholm H, Kosteljanetz M, Poulsen HS. Michaelsen SR, et al. Among authors: kosteljanetz m. BMC Cancer. 2013 Sep 3;13:402. doi: 10.1186/1471-2407-13-402. BMC Cancer. 2013. PMID: 24004722 Free PMC article.
Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan.
Toft A, Urup T, Christensen IJ, Michaelsen SR, Lukram B, Grunnet K, Kosteljanetz M, Larsen VA, Lassen U, Broholm H, Poulsen HS. Toft A, et al. Among authors: kosteljanetz m. Cancer Invest. 2018 Feb 7;36(2):165-174. doi: 10.1080/07357907.2018.1430818. Epub 2018 Feb 2. Cancer Invest. 2018. PMID: 29393706 Review.
Incidence and late prognosis of cushing's syndrome: a population-based study.
Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J. Lindholm J, et al. Among authors: kosteljanetz m. J Clin Endocrinol Metab. 2001 Jan;86(1):117-23. doi: 10.1210/jcem.86.1.7093. J Clin Endocrinol Metab. 2001. PMID: 11231987
Fractionated stereotactic radiotherapy in patients with acromegaly: an interim single-centre audit.
Roug S, Rasmussen AK, Juhler M, Kosteljanetz M, Poulsgaard L, Heebøll H, Roed H, Feldt-Rasmussen U. Roug S, et al. Among authors: kosteljanetz m. Eur J Endocrinol. 2010 Apr;162(4):685-94. doi: 10.1530/EJE-09-1045. Epub 2010 Feb 4. Eur J Endocrinol. 2010. PMID: 20133445
95 results
Jump to page
Feedback